TimesSquare Capital Management LLC Grows Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

TimesSquare Capital Management LLC raised its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 39.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 158,868 shares of the company's stock after purchasing an additional 44,646 shares during the quarter. TimesSquare Capital Management LLC owned 0.55% of Krystal Biotech worth $24,888,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Summit Trail Advisors LLC purchased a new stake in shares of Krystal Biotech during the third quarter valued at approximately $1,893,000. Entropy Technologies LP bought a new position in Krystal Biotech during the fourth quarter valued at $548,000. Swiss National Bank grew its holdings in Krystal Biotech by 8.0% during the third quarter. Swiss National Bank now owns 39,100 shares of the company's stock valued at $7,117,000 after purchasing an additional 2,900 shares during the period. Janney Montgomery Scott LLC grew its holdings in Krystal Biotech by 42.0% during the fourth quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company's stock valued at $8,239,000 after purchasing an additional 15,545 shares during the period. Finally, Citigroup Inc. grew its holdings in Krystal Biotech by 65.4% during the third quarter. Citigroup Inc. now owns 35,084 shares of the company's stock valued at $6,386,000 after purchasing an additional 13,874 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares in the company, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 14.10% of the company's stock.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock traded up $4.75 during trading hours on Friday, reaching $187.37. The company had a trading volume of 170,100 shares, compared to its average volume of 256,999. Krystal Biotech, Inc. has a one year low of $107.50 and a one year high of $219.34. The business has a fifty day simple moving average of $157.37 and a 200 day simple moving average of $175.23. The firm has a market cap of $5.39 billion, a PE ratio of 62.77 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same quarter last year, the business posted $0.30 earnings per share. The company's revenue for the quarter was up 116.4% on a year-over-year basis. On average, research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Analysts Set New Price Targets

KRYS has been the subject of several research reports. Chardan Capital increased their price objective on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a report on Thursday. HC Wainwright reissued a "buy" rating and set a $221.00 price objective on shares of Krystal Biotech in a report on Wednesday. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday. Finally, Citigroup increased their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a report on Thursday. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Krystal Biotech currently has a consensus rating of "Buy" and a consensus target price of $210.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).